Pipeline expanded with gene therapy technologies including AXO-Lenti-PD for treatment of Parkinson’s Disease and AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy   Ilise Lombardo , MD, promoted to Chief Medical Officer   Leadership and advisory team broadened with experts in gene

License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional protein Plan to initiate placebo-controlled study of AXO-AAV-OPMD in patients with oculopharyngeal

BASEL, Switzerland , June 18, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET .

Exclusive worldwide license to lentiviral vector gene therapy constitutes the first transaction of Axovant’s 2018 pipeline expansion Fraser Wright , Co-Founder and former Chief Technology Officer of Spark Therapeutics , to join Axovant as CTO for gene therapy programs Axovant will receive $25

BASEL, Switzerland , May 31, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on June 7, 2018 at 9:00 a.m.

Gavin Corcoran , current Chief Medical Officer of Allergan plc , to join Axovant as EVP of R&D Michael Hayden , former Chief Scientific Officer and President of Global R&D at Teva, to serve as Chairman of Axovant’s Scientific Advisory Board Organizational restructuring completed in preparation for

Dr. David Hung resigns as CEO and continues as scientific advisor to Roivant family of companies Dr. Pavan Cheruvu appointed as CEO of Axovant Dr. Roger Jeffs , former President and co-CEO of United Therapeutics , and George Bickerstaff , former CFO of Novartis Pharma, join board of directors

BASEL, Switzerland , Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced a correction to the data related to the Company’s investigational drug nelotanserin previously reported in its January 8, 2018 press release. In the results of the pilot Phase 2 Visual

-- Intepirdine Program to be Discontinued Based on MINDSET, HEADWAY,  and Gait and Balance Study Results -- -- Company to Advance to Larger Confirmatory Nelotanserin DLB Study  Focused on Motor Function and Psychosis -- -- Conference Call Today at 8:00 a.m. EST -- BASEL, Switzerland , Jan.

BASEL, Switzerland , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that its Chief Executive Officer David Hung , MD, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 th at 10:00 a.m. PST at the Westin St.